BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Identifieur interne : 002276 ( PubMed/Checkpoint ); précédent : 002275; suivant : 002277BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Auteurs : Philipp Harter [Allemagne] ; Toby Johnson [Royaume-Uni] ; Dominique Berton-Rigaud [France] ; Sang-Yoon Park [Corée du Sud] ; Michael Friedlander [Australie] ; Josep M. Del Campo [Espagne] ; Muneaki Shimada [Japon] ; Frédéric Forget [Belgique] ; Mansoor R. Mirza [Danemark] ; Nicoletta Colombo [Italie] ; Claudio Zamagni [Italie] ; John K. Chan [États-Unis] ; Martin Imhof [Autriche] ; Thomas J. Herzog [États-Unis] ; Dearbhaile O'Donnell [Irlande (pays)] ; Florian Heitz [Allemagne] ; Karen King [États-Unis] ; Sandy Stinnett [États-Unis] ; Catherine Barrett [Suisse] ; Minesh Jobanputra [Royaume-Uni] ; Chun-Fang Xu [Royaume-Uni] ; Andreas Du Bois [Allemagne]Source :
- Gynecologic oncology [ 1095-6859 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antinéoplasiques (usage thérapeutique), Chimiothérapie de maintenance, Femelle, Gène BRCA1, Gène BRCA2, Humains, Jeune adulte, Mutation germinale, Population d'origine asiatique (génétique), Population d'origine européenne (génétique), Pyrimidines (usage thérapeutique), Sujet âgé, Sujet âgé de 80 ans ou plus, Sulfonamides (usage thérapeutique), Survie sans rechute, Tumeurs de l'ovaire (génétique), Tumeurs de l'ovaire (traitement médicamenteux), Tumeurs de la trompe de Fallope (génétique), Tumeurs de la trompe de Fallope (traitement médicamenteux), Tumeurs du péritoine (génétique), Tumeurs du péritoine (traitement médicamenteux), Tumeurs épithéliales épidermoïdes et glandulaires (génétique), Tumeurs épithéliales épidermoïdes et glandulaires (traitement médicamenteux), Étude d'association pangénomique.
- MESH :
- génétique : Population d'origine asiatique, Population d'origine européenne, Tumeurs de l'ovaire, Tumeurs de la trompe de Fallope, Tumeurs du péritoine, Tumeurs épithéliales épidermoïdes et glandulaires.
- traitement médicamenteux : Tumeurs de l'ovaire, Tumeurs de la trompe de Fallope, Tumeurs du péritoine, Tumeurs épithéliales épidermoïdes et glandulaires.
- usage thérapeutique : Antinéoplasiques, Pyrimidines, Sulfonamides.
- Adulte, Adulte d'âge moyen, Chimiothérapie de maintenance, Femelle, Gène BRCA1, Gène BRCA2, Humains, Jeune adulte, Mutation germinale, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Étude d'association pangénomique.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents (therapeutic use), Asian Continental Ancestry Group (genetics), Disease-Free Survival, European Continental Ancestry Group (genetics), Fallopian Tube Neoplasms (drug therapy), Fallopian Tube Neoplasms (genetics), Female, Genes, BRCA1, Genes, BRCA2, Genome-Wide Association Study, Germ-Line Mutation, Humans, Maintenance Chemotherapy, Middle Aged, Neoplasms, Glandular and Epithelial (drug therapy), Neoplasms, Glandular and Epithelial (genetics), Ovarian Neoplasms (drug therapy), Ovarian Neoplasms (genetics), Peritoneal Neoplasms (drug therapy), Peritoneal Neoplasms (genetics), Pyrimidines (therapeutic use), Sulfonamides (therapeutic use), Young Adult.
- MESH :
- chemical , therapeutic use : Antineoplastic Agents, Pyrimidines, Sulfonamides.
- drug therapy : Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms.
- genetics : Asian Continental Ancestry Group, European Continental Ancestry Group, Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms.
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Genes, BRCA1, Genes, BRCA2, Genome-Wide Association Study, Germ-Line Mutation, Humans, Maintenance Chemotherapy, Middle Aged, Young Adult.
Abstract
AGO-OVAR 16 demonstrated that pazopanib maintenance therapy significantly increased progression-free survival (PFS) in patients with ovarian cancer whose disease had not progressed after first-line therapy. In a sub-study, we evaluated the effect of clinically important germline BRCA1 and BRCA2 mutations on PFS.
DOI: 10.1016/j.ygyno.2015.12.027
PubMed: 26740259
Affiliations:
- Allemagne, Australie, Autriche, Belgique, Corée du Sud, Danemark, Espagne, France, Irlande (pays), Italie, Japon, Royaume-Uni, Suisse, États-Unis
- Californie, Caroline du Nord, Catalogne, Hovedstaden, Lombardie, Ohio
- Barcelone, Copenhague, Milan
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26740259Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.</title><author><name sortKey="Harter, Philipp" sort="Harter, Philipp" uniqKey="Harter P" first="Philipp" last="Harter">Philipp Harter</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany. Electronic address: p.harter@gmx.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen</wicri:regionArea><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion></affiliation></author><author><name sortKey="Johnson, Toby" sort="Johnson, Toby" uniqKey="Johnson T" first="Toby" last="Johnson">Toby Johnson</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY</wicri:regionArea><wicri:noRegion>Stevenage SG1 2NY</wicri:noRegion></affiliation></author><author><name sortKey="Berton Rigaud, Dominique" sort="Berton Rigaud, Dominique" uniqKey="Berton Rigaud D" first="Dominique" last="Berton-Rigaud">Dominique Berton-Rigaud</name><affiliation wicri:level="1"><nlm:affiliation>Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Saint-Herblain, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Saint-Herblain</wicri:regionArea><wicri:noRegion>Saint-Herblain</wicri:noRegion><wicri:noRegion>Saint-Herblain</wicri:noRegion></affiliation></author><author><name sortKey="Park, Sang Yoon" sort="Park, Sang Yoon" uniqKey="Park S" first="Sang-Yoon" last="Park">Sang-Yoon Park</name><affiliation wicri:level="1"><nlm:affiliation>National Cancer Center, Goyang, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>National Cancer Center, Goyang</wicri:regionArea><wicri:noRegion>Goyang</wicri:noRegion></affiliation></author><author><name sortKey="Friedlander, Michael" sort="Friedlander, Michael" uniqKey="Friedlander M" first="Michael" last="Friedlander">Michael Friedlander</name><affiliation wicri:level="1"><nlm:affiliation>The Prince of Wales Clinical School University of New South Wales, Randwick, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Prince of Wales Clinical School University of New South Wales, Randwick, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Del Campo, Josep M" sort="Del Campo, Josep M" uniqKey="Del Campo J" first="Josep M" last="Del Campo">Josep M. Del Campo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Shimada, Muneaki" sort="Shimada, Muneaki" uniqKey="Shimada M" first="Muneaki" last="Shimada">Muneaki Shimada</name><affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynecology, Tottori University School of Medicine, Nishimachi, Yonago, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Obstetrics and Gynecology, Tottori University School of Medicine, Nishimachi, Yonago</wicri:regionArea><wicri:noRegion>Yonago</wicri:noRegion></affiliation></author><author><name sortKey="Forget, Frederic" sort="Forget, Frederic" uniqKey="Forget F" first="Frédéric" last="Forget">Frédéric Forget</name><affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier de l'Ardenne, Libramont, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Centre Hospitalier de l'Ardenne, Libramont</wicri:regionArea><wicri:noRegion>Libramont</wicri:noRegion></affiliation></author><author><name sortKey="Mirza, Mansoor R" sort="Mirza, Mansoor R" uniqKey="Mirza M" first="Mansoor R" last="Mirza">Mansoor R. Mirza</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Rigshospitalet, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Oncology, Rigshospitalet, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Colombo, Nicoletta" sort="Colombo, Nicoletta" uniqKey="Colombo N" first="Nicoletta" last="Colombo">Nicoletta Colombo</name><affiliation wicri:level="3"><nlm:affiliation>Gynecologic Oncology, University of Milan-Bicocca and European Institute of Oncology, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Gynecologic Oncology, University of Milan-Bicocca and European Institute of Oncology, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Zamagni, Claudio" sort="Zamagni, Claudio" uniqKey="Zamagni C" first="Claudio" last="Zamagni">Claudio Zamagni</name><affiliation wicri:level="1"><nlm:affiliation>S. Orsola-Malpighi University Hospital, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>S. Orsola-Malpighi University Hospital, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Chan, John K" sort="Chan, John K" uniqKey="Chan J" first="John K" last="Chan">John K. Chan</name><affiliation wicri:level="2"><nlm:affiliation>California Pacific and Palo Alto Sutter Cancer Research Institute, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>California Pacific and Palo Alto Sutter Cancer Research Institute, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Imhof, Martin" sort="Imhof, Martin" uniqKey="Imhof M" first="Martin" last="Imhof">Martin Imhof</name><affiliation wicri:level="1"><nlm:affiliation>Regional Hospital Korneuburg, Medical University of Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Regional Hospital Korneuburg, Medical University of Vienna</wicri:regionArea><wicri:noRegion>Medical University of Vienna</wicri:noRegion></affiliation></author><author><name sortKey="Herzog, Thomas J" sort="Herzog, Thomas J" uniqKey="Herzog T" first="Thomas J" last="Herzog">Thomas J. Herzog</name><affiliation wicri:level="2"><nlm:affiliation>University of Cincinnati Cancer Institute, Cincinnati, OH, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Cincinnati Cancer Institute, Cincinnati, OH</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation></author><author><name sortKey="O Donnell, Dearbhaile" sort="O Donnell, Dearbhaile" uniqKey="O Donnell D" first="Dearbhaile" last="O'Donnell">Dearbhaile O'Donnell</name><affiliation wicri:level="1"><nlm:affiliation>All Ireland Cooperative Oncology Research Group, Dublin, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>All Ireland Cooperative Oncology Research Group, Dublin</wicri:regionArea><wicri:noRegion>Dublin</wicri:noRegion></affiliation></author><author><name sortKey="Heitz, Florian" sort="Heitz, Florian" uniqKey="Heitz F" first="Florian" last="Heitz">Florian Heitz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen</wicri:regionArea><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion></affiliation></author><author><name sortKey="King, Karen" sort="King, Karen" uniqKey="King K" first="Karen" last="King">Karen King</name><affiliation wicri:level="2"><nlm:affiliation>Parexel International, Durham, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parexel International, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Stinnett, Sandy" sort="Stinnett, Sandy" uniqKey="Stinnett S" first="Sandy" last="Stinnett">Sandy Stinnett</name><affiliation wicri:level="2"><nlm:affiliation>Parexel International, Durham, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parexel International, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Barrett, Catherine" sort="Barrett, Catherine" uniqKey="Barrett C" first="Catherine" last="Barrett">Catherine Barrett</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Jobanputra, Minesh" sort="Jobanputra, Minesh" uniqKey="Jobanputra M" first="Minesh" last="Jobanputra">Minesh Jobanputra</name><affiliation wicri:level="1"><nlm:affiliation>Biogen Idec, Berkshire, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Biogen Idec, Berkshire</wicri:regionArea><wicri:noRegion>Berkshire</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Chun Fang" sort="Xu, Chun Fang" uniqKey="Xu C" first="Chun-Fang" last="Xu">Chun-Fang Xu</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY</wicri:regionArea><wicri:noRegion>Stevenage SG1 2NY</wicri:noRegion></affiliation></author><author><name sortKey="Du Bois, Andreas" sort="Du Bois, Andreas" uniqKey="Du Bois A" first="Andreas" last="Du Bois">Andreas Du Bois</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen</wicri:regionArea><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26740259</idno><idno type="pmid">26740259</idno><idno type="doi">10.1016/j.ygyno.2015.12.027</idno><idno type="wicri:Area/PubMed/Corpus">002144</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002144</idno><idno type="wicri:Area/PubMed/Curation">002118</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002118</idno><idno type="wicri:Area/PubMed/Checkpoint">002118</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002118</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.</title><author><name sortKey="Harter, Philipp" sort="Harter, Philipp" uniqKey="Harter P" first="Philipp" last="Harter">Philipp Harter</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany. Electronic address: p.harter@gmx.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen</wicri:regionArea><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion></affiliation></author><author><name sortKey="Johnson, Toby" sort="Johnson, Toby" uniqKey="Johnson T" first="Toby" last="Johnson">Toby Johnson</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY</wicri:regionArea><wicri:noRegion>Stevenage SG1 2NY</wicri:noRegion></affiliation></author><author><name sortKey="Berton Rigaud, Dominique" sort="Berton Rigaud, Dominique" uniqKey="Berton Rigaud D" first="Dominique" last="Berton-Rigaud">Dominique Berton-Rigaud</name><affiliation wicri:level="1"><nlm:affiliation>Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Saint-Herblain, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Saint-Herblain</wicri:regionArea><wicri:noRegion>Saint-Herblain</wicri:noRegion><wicri:noRegion>Saint-Herblain</wicri:noRegion></affiliation></author><author><name sortKey="Park, Sang Yoon" sort="Park, Sang Yoon" uniqKey="Park S" first="Sang-Yoon" last="Park">Sang-Yoon Park</name><affiliation wicri:level="1"><nlm:affiliation>National Cancer Center, Goyang, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>National Cancer Center, Goyang</wicri:regionArea><wicri:noRegion>Goyang</wicri:noRegion></affiliation></author><author><name sortKey="Friedlander, Michael" sort="Friedlander, Michael" uniqKey="Friedlander M" first="Michael" last="Friedlander">Michael Friedlander</name><affiliation wicri:level="1"><nlm:affiliation>The Prince of Wales Clinical School University of New South Wales, Randwick, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Prince of Wales Clinical School University of New South Wales, Randwick, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Del Campo, Josep M" sort="Del Campo, Josep M" uniqKey="Del Campo J" first="Josep M" last="Del Campo">Josep M. Del Campo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Shimada, Muneaki" sort="Shimada, Muneaki" uniqKey="Shimada M" first="Muneaki" last="Shimada">Muneaki Shimada</name><affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynecology, Tottori University School of Medicine, Nishimachi, Yonago, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Obstetrics and Gynecology, Tottori University School of Medicine, Nishimachi, Yonago</wicri:regionArea><wicri:noRegion>Yonago</wicri:noRegion></affiliation></author><author><name sortKey="Forget, Frederic" sort="Forget, Frederic" uniqKey="Forget F" first="Frédéric" last="Forget">Frédéric Forget</name><affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier de l'Ardenne, Libramont, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Centre Hospitalier de l'Ardenne, Libramont</wicri:regionArea><wicri:noRegion>Libramont</wicri:noRegion></affiliation></author><author><name sortKey="Mirza, Mansoor R" sort="Mirza, Mansoor R" uniqKey="Mirza M" first="Mansoor R" last="Mirza">Mansoor R. Mirza</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Rigshospitalet, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Oncology, Rigshospitalet, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Colombo, Nicoletta" sort="Colombo, Nicoletta" uniqKey="Colombo N" first="Nicoletta" last="Colombo">Nicoletta Colombo</name><affiliation wicri:level="3"><nlm:affiliation>Gynecologic Oncology, University of Milan-Bicocca and European Institute of Oncology, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Gynecologic Oncology, University of Milan-Bicocca and European Institute of Oncology, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Zamagni, Claudio" sort="Zamagni, Claudio" uniqKey="Zamagni C" first="Claudio" last="Zamagni">Claudio Zamagni</name><affiliation wicri:level="1"><nlm:affiliation>S. Orsola-Malpighi University Hospital, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>S. Orsola-Malpighi University Hospital, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Chan, John K" sort="Chan, John K" uniqKey="Chan J" first="John K" last="Chan">John K. Chan</name><affiliation wicri:level="2"><nlm:affiliation>California Pacific and Palo Alto Sutter Cancer Research Institute, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>California Pacific and Palo Alto Sutter Cancer Research Institute, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Imhof, Martin" sort="Imhof, Martin" uniqKey="Imhof M" first="Martin" last="Imhof">Martin Imhof</name><affiliation wicri:level="1"><nlm:affiliation>Regional Hospital Korneuburg, Medical University of Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Regional Hospital Korneuburg, Medical University of Vienna</wicri:regionArea><wicri:noRegion>Medical University of Vienna</wicri:noRegion></affiliation></author><author><name sortKey="Herzog, Thomas J" sort="Herzog, Thomas J" uniqKey="Herzog T" first="Thomas J" last="Herzog">Thomas J. Herzog</name><affiliation wicri:level="2"><nlm:affiliation>University of Cincinnati Cancer Institute, Cincinnati, OH, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Cincinnati Cancer Institute, Cincinnati, OH</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation></author><author><name sortKey="O Donnell, Dearbhaile" sort="O Donnell, Dearbhaile" uniqKey="O Donnell D" first="Dearbhaile" last="O'Donnell">Dearbhaile O'Donnell</name><affiliation wicri:level="1"><nlm:affiliation>All Ireland Cooperative Oncology Research Group, Dublin, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>All Ireland Cooperative Oncology Research Group, Dublin</wicri:regionArea><wicri:noRegion>Dublin</wicri:noRegion></affiliation></author><author><name sortKey="Heitz, Florian" sort="Heitz, Florian" uniqKey="Heitz F" first="Florian" last="Heitz">Florian Heitz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen</wicri:regionArea><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion></affiliation></author><author><name sortKey="King, Karen" sort="King, Karen" uniqKey="King K" first="Karen" last="King">Karen King</name><affiliation wicri:level="2"><nlm:affiliation>Parexel International, Durham, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parexel International, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Stinnett, Sandy" sort="Stinnett, Sandy" uniqKey="Stinnett S" first="Sandy" last="Stinnett">Sandy Stinnett</name><affiliation wicri:level="2"><nlm:affiliation>Parexel International, Durham, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parexel International, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Barrett, Catherine" sort="Barrett, Catherine" uniqKey="Barrett C" first="Catherine" last="Barrett">Catherine Barrett</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Jobanputra, Minesh" sort="Jobanputra, Minesh" uniqKey="Jobanputra M" first="Minesh" last="Jobanputra">Minesh Jobanputra</name><affiliation wicri:level="1"><nlm:affiliation>Biogen Idec, Berkshire, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Biogen Idec, Berkshire</wicri:regionArea><wicri:noRegion>Berkshire</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Chun Fang" sort="Xu, Chun Fang" uniqKey="Xu C" first="Chun-Fang" last="Xu">Chun-Fang Xu</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY</wicri:regionArea><wicri:noRegion>Stevenage SG1 2NY</wicri:noRegion></affiliation></author><author><name sortKey="Du Bois, Andreas" sort="Du Bois, Andreas" uniqKey="Du Bois A" first="Andreas" last="Du Bois">Andreas Du Bois</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen</wicri:regionArea><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion></affiliation></author></analytic><series><title level="j">Gynecologic oncology</title><idno type="eISSN">1095-6859</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Agents (therapeutic use)</term><term>Asian Continental Ancestry Group (genetics)</term><term>Disease-Free Survival</term><term>European Continental Ancestry Group (genetics)</term><term>Fallopian Tube Neoplasms (drug therapy)</term><term>Fallopian Tube Neoplasms (genetics)</term><term>Female</term><term>Genes, BRCA1</term><term>Genes, BRCA2</term><term>Genome-Wide Association Study</term><term>Germ-Line Mutation</term><term>Humans</term><term>Maintenance Chemotherapy</term><term>Middle Aged</term><term>Neoplasms, Glandular and Epithelial (drug therapy)</term><term>Neoplasms, Glandular and Epithelial (genetics)</term><term>Ovarian Neoplasms (drug therapy)</term><term>Ovarian Neoplasms (genetics)</term><term>Peritoneal Neoplasms (drug therapy)</term><term>Peritoneal Neoplasms (genetics)</term><term>Pyrimidines (therapeutic use)</term><term>Sulfonamides (therapeutic use)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Chimiothérapie de maintenance</term><term>Femelle</term><term>Gène BRCA1</term><term>Gène BRCA2</term><term>Humains</term><term>Jeune adulte</term><term>Mutation germinale</term><term>Population d'origine asiatique (génétique)</term><term>Population d'origine européenne (génétique)</term><term>Pyrimidines (usage thérapeutique)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Sulfonamides (usage thérapeutique)</term><term>Survie sans rechute</term><term>Tumeurs de l'ovaire (génétique)</term><term>Tumeurs de l'ovaire (traitement médicamenteux)</term><term>Tumeurs de la trompe de Fallope (génétique)</term><term>Tumeurs de la trompe de Fallope (traitement médicamenteux)</term><term>Tumeurs du péritoine (génétique)</term><term>Tumeurs du péritoine (traitement médicamenteux)</term><term>Tumeurs épithéliales épidermoïdes et glandulaires (génétique)</term><term>Tumeurs épithéliales épidermoïdes et glandulaires (traitement médicamenteux)</term><term>Étude d'association pangénomique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Pyrimidines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Fallopian Tube Neoplasms</term><term>Neoplasms, Glandular and Epithelial</term><term>Ovarian Neoplasms</term><term>Peritoneal Neoplasms</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Asian Continental Ancestry Group</term><term>European Continental Ancestry Group</term><term>Fallopian Tube Neoplasms</term><term>Neoplasms, Glandular and Epithelial</term><term>Ovarian Neoplasms</term><term>Peritoneal Neoplasms</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Population d'origine asiatique</term><term>Population d'origine européenne</term><term>Tumeurs de l'ovaire</term><term>Tumeurs de la trompe de Fallope</term><term>Tumeurs du péritoine</term><term>Tumeurs épithéliales épidermoïdes et glandulaires</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs de l'ovaire</term><term>Tumeurs de la trompe de Fallope</term><term>Tumeurs du péritoine</term><term>Tumeurs épithéliales épidermoïdes et glandulaires</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Pyrimidines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disease-Free Survival</term><term>Female</term><term>Genes, BRCA1</term><term>Genes, BRCA2</term><term>Genome-Wide Association Study</term><term>Germ-Line Mutation</term><term>Humans</term><term>Maintenance Chemotherapy</term><term>Middle Aged</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Chimiothérapie de maintenance</term><term>Femelle</term><term>Gène BRCA1</term><term>Gène BRCA2</term><term>Humains</term><term>Jeune adulte</term><term>Mutation germinale</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Étude d'association pangénomique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">AGO-OVAR 16 demonstrated that pazopanib maintenance therapy significantly increased progression-free survival (PFS) in patients with ovarian cancer whose disease had not progressed after first-line therapy. In a sub-study, we evaluated the effect of clinically important germline BRCA1 and BRCA2 mutations on PFS.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26740259</PMID><DateCreated><Year>2016</Year><Month>02</Month><Day>24</Day></DateCreated><DateCompleted><Year>2016</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2016</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-6859</ISSN><JournalIssue CitedMedium="Internet"><Volume>140</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Gynecologic oncology</Title><ISOAbbreviation>Gynecol. Oncol.</ISOAbbreviation></Journal><ArticleTitle>BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.</ArticleTitle><Pagination><MedlinePgn>443-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ygyno.2015.12.027</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0090-8258(15)30230-4</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">AGO-OVAR 16 demonstrated that pazopanib maintenance therapy significantly increased progression-free survival (PFS) in patients with ovarian cancer whose disease had not progressed after first-line therapy. In a sub-study, we evaluated the effect of clinically important germline BRCA1 and BRCA2 mutations on PFS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Of 940 AGO-OVAR 16 participants, 664 had BRCA1/2 exon sequencing data (pazopanib, n=335; placebo, n=329). A Cox model was used to test the association between genetic variants and PFS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ninety-seven of 664 patients (15%) carried clinically important BRCA1/2 mutations (BRCA1/2 carriers: pazopanib 14%, placebo 16%). Median PFS was longer in BRCA1/2 mutation carriers than in BRCA1/2 non-carriers in the placebo arm (30.3 vs 14.1 months, hazard ratio, 0.48; 95% confidence interval [CI]: 0.29-0.78; P=0.0031); a similar non-significant trend was noted with pazopanib (30.2 vs 17.7 months, hazard ratio, 0.64; 95% CI: 0.40-1.03; P=0.069). Among BRCA1/2 non-carriers, PFS was longer for pazopanib-treated patients than placebo-treated patients (17.7 vs 14.1 months, hazard ratio, 0.77; 95% CI: 0.62-0.97; P=0.024). Among BRCA1/2 carriers, there was no significant PFS difference between treatments, although numbers were small (pazopanib, 46; placebo, 51), resulting in a wide CI (hazard ratio, 1.36; 95% CI: 0.66-2.82).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with clinically important BRCA1/2 mutations had better prognosis. BRCA1/2 mutation status might be added as strata in future trials in primary ovarian cancer.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harter</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany. Electronic address: p.harter@gmx.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Toby</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berton-Rigaud</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Saint-Herblain, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sang-Yoon</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>National Cancer Center, Goyang, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedlander</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Prince of Wales Clinical School University of New South Wales, Randwick, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Campo</LastName><ForeName>Josep M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimada</LastName><ForeName>Muneaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Tottori University School of Medicine, Nishimachi, Yonago, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forget</LastName><ForeName>Frédéric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre Hospitalier de l'Ardenne, Libramont, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirza</LastName><ForeName>Mansoor R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Oncology, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Nicoletta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Gynecologic Oncology, University of Milan-Bicocca and European Institute of Oncology, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamagni</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>S. Orsola-Malpighi University Hospital, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>John K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>California Pacific and Palo Alto Sutter Cancer Research Institute, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imhof</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Regional Hospital Korneuburg, Medical University of Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herzog</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>University of Cincinnati Cancer Institute, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Donnell</LastName><ForeName>Dearbhaile</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>All Ireland Cooperative Oncology Research Group, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heitz</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Parexel International, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stinnett</LastName><ForeName>Sandy</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Parexel International, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Novartis Pharma AG, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jobanputra</LastName><ForeName>Minesh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biogen Idec, Berkshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Chun-Fang</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>du Bois</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gynecol Oncol</MedlineTA><NlmUniqueID>0365304</NlmUniqueID><ISSNLinking>0090-8258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>7RN5DR86CK</RegistryNumber><NameOfSubstance UI="C516667">pazopanib</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C538090">Ovarian epithelial cancer</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian Continental Ancestry Group</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005185" MajorTopicYN="N">Fallopian Tube Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019398" MajorTopicYN="Y">Genes, BRCA1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024522" MajorTopicYN="Y">Genes, BRCA2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018095" MajorTopicYN="Y">Germ-Line Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060046" MajorTopicYN="N">Maintenance Chemotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009375" MajorTopicYN="N">Neoplasms, Glandular and Epithelial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010534" MajorTopicYN="N">Peritoneal Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GWAS</Keyword><Keyword MajorTopicYN="N">Germline BRCA mutation</Keyword><Keyword MajorTopicYN="N">Ovarian cancer</Keyword><Keyword MajorTopicYN="N">Pazopanib</Keyword><Keyword MajorTopicYN="N">Progression-free survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26740259</ArticleId><ArticleId IdType="pii">S0090-8258(15)30230-4</ArticleId><ArticleId IdType="doi">10.1016/j.ygyno.2015.12.027</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Autriche</li><li>Belgique</li><li>Corée du Sud</li><li>Danemark</li><li>Espagne</li><li>France</li><li>Irlande (pays)</li><li>Italie</li><li>Japon</li><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Californie</li><li>Caroline du Nord</li><li>Catalogne</li><li>Hovedstaden</li><li>Lombardie</li><li>Ohio</li></region><settlement><li>Barcelone</li><li>Copenhague</li><li>Milan</li></settlement></list><tree><country name="Allemagne"><noRegion><name sortKey="Harter, Philipp" sort="Harter, Philipp" uniqKey="Harter P" first="Philipp" last="Harter">Philipp Harter</name></noRegion><name sortKey="Du Bois, Andreas" sort="Du Bois, Andreas" uniqKey="Du Bois A" first="Andreas" last="Du Bois">Andreas Du Bois</name><name sortKey="Heitz, Florian" sort="Heitz, Florian" uniqKey="Heitz F" first="Florian" last="Heitz">Florian Heitz</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Johnson, Toby" sort="Johnson, Toby" uniqKey="Johnson T" first="Toby" last="Johnson">Toby Johnson</name></noRegion><name sortKey="Jobanputra, Minesh" sort="Jobanputra, Minesh" uniqKey="Jobanputra M" first="Minesh" last="Jobanputra">Minesh Jobanputra</name><name sortKey="Xu, Chun Fang" sort="Xu, Chun Fang" uniqKey="Xu C" first="Chun-Fang" last="Xu">Chun-Fang Xu</name></country><country name="France"><noRegion><name sortKey="Berton Rigaud, Dominique" sort="Berton Rigaud, Dominique" uniqKey="Berton Rigaud D" first="Dominique" last="Berton-Rigaud">Dominique Berton-Rigaud</name></noRegion></country><country name="Corée du Sud"><noRegion><name sortKey="Park, Sang Yoon" sort="Park, Sang Yoon" uniqKey="Park S" first="Sang-Yoon" last="Park">Sang-Yoon Park</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Friedlander, Michael" sort="Friedlander, Michael" uniqKey="Friedlander M" first="Michael" last="Friedlander">Michael Friedlander</name></noRegion></country><country name="Espagne"><region name="Catalogne"><name sortKey="Del Campo, Josep M" sort="Del Campo, Josep M" uniqKey="Del Campo J" first="Josep M" last="Del Campo">Josep M. Del Campo</name></region></country><country name="Japon"><noRegion><name sortKey="Shimada, Muneaki" sort="Shimada, Muneaki" uniqKey="Shimada M" first="Muneaki" last="Shimada">Muneaki Shimada</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="Forget, Frederic" sort="Forget, Frederic" uniqKey="Forget F" first="Frédéric" last="Forget">Frédéric Forget</name></noRegion></country><country name="Danemark"><region name="Hovedstaden"><name sortKey="Mirza, Mansoor R" sort="Mirza, Mansoor R" uniqKey="Mirza M" first="Mansoor R" last="Mirza">Mansoor R. Mirza</name></region></country><country name="Italie"><region name="Lombardie"><name sortKey="Colombo, Nicoletta" sort="Colombo, Nicoletta" uniqKey="Colombo N" first="Nicoletta" last="Colombo">Nicoletta Colombo</name></region><name sortKey="Zamagni, Claudio" sort="Zamagni, Claudio" uniqKey="Zamagni C" first="Claudio" last="Zamagni">Claudio Zamagni</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Chan, John K" sort="Chan, John K" uniqKey="Chan J" first="John K" last="Chan">John K. Chan</name></region><name sortKey="Herzog, Thomas J" sort="Herzog, Thomas J" uniqKey="Herzog T" first="Thomas J" last="Herzog">Thomas J. Herzog</name><name sortKey="King, Karen" sort="King, Karen" uniqKey="King K" first="Karen" last="King">Karen King</name><name sortKey="Stinnett, Sandy" sort="Stinnett, Sandy" uniqKey="Stinnett S" first="Sandy" last="Stinnett">Sandy Stinnett</name></country><country name="Autriche"><noRegion><name sortKey="Imhof, Martin" sort="Imhof, Martin" uniqKey="Imhof M" first="Martin" last="Imhof">Martin Imhof</name></noRegion></country><country name="Irlande (pays)"><noRegion><name sortKey="O Donnell, Dearbhaile" sort="O Donnell, Dearbhaile" uniqKey="O Donnell D" first="Dearbhaile" last="O'Donnell">Dearbhaile O'Donnell</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Barrett, Catherine" sort="Barrett, Catherine" uniqKey="Barrett C" first="Catherine" last="Barrett">Catherine Barrett</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002276 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002276 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26740259
|texte= BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26740259" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |